In an ageing population, a greater proportion of geriatric patients will be considered for systemic chemotherapy. Colorectal cancer (CRC) is a common malignancy and will be a major health issue in geriatrics. We used the MAX population to investigate whether age affected the improved outcome found in CRC when bevacizumab is added to capecitabine chemotherapy.
introduction
Ageing of our population is occurring worldwide. The majority of patients diagnosed with cancer will fit the definition of elderly or even geriatric and importantly for advanced colorectal cancer (CRC), over one-third of our patients will be aged over 75 years [1] . Ageing involves a progressive decline in functional reserve and increased frequency of co-morbidity and chronic disease. Thus, oncologists will be faced with increasing frequency of CRC in an ageing population with potentially declining general health.
Patients over 75 years were sometimes historically excluded from clinical trials. Even when not specifically excluded, patients over 70 years often make up <20% of the total patient group, and consequently, the number of patients over 75 years is relatively small, leading to the general criticism that trials are not representative of the patient population outside studies. Pooled analysis is often undertaken to assess age and chemotherapy outcome. Interpreting the results available is also complex as the definition of 'elderly' often varies in the literature (>65, >70 and >75 years are frequently defined age groups).
Despite the lack of specifically designed randomised trials in the elderly, there is evidence that the tolerance and outcome of 5-fluorouracil (5-FU), irinotecan and oxaliplatin chemotherapy in older patients with CRC are acceptable and often not obviously different from younger populations [2] . Despite this, there is also population-based evidence indicating that clinicians tend to be conservative when considering therapy in the elderly either not proceeding or reducing the dose of chemotherapy [3] . In some circumstances, this is justified. For example, there is an increased risk of toxicity from the oral fluoropyrimidine capecitabine (C), when there is poor renal function, which declines with age [4] .
With the addition of biological agents, new toxic effects need to be considered, in particular for bevacizumab, where there appears to be higher rates of arterial thromboembolic disease reported than with chemotherapy alone [5] and there may be a relationship to age. There is, however, little to suggest that the overall tolerance and outcome of bevacizumab and chemotherapy combination therapy are altered by age alone [6] .
As the MAX trial [7] included an older population overall than generally reported (median age 67-69 years), we have undertaken an analysis of patients, who we have defined as elderly or geriatric ( ‡75 years). The aims of this analysis are to assess the impact of age on outcome, tolerance and dose intensity of chemotherapy alone or in combination with bevacizumab.
methods
The MAX trial was an international, multicentre randomised phase II/III study in metastatic CRC of capecitabine (C) versus capecitabine/ bevacizumab (CB) versus CB and mitomycin C (MMC) (CBM), which demonstrated an improvement in progression-free survival (PFS) with the addition of bevacizumab (with or without mitomycin C) to capecitabine [7] . The trial used a capecitabine dose of 2500 mg/m 2 for 14 days with a 7-day break, although clinicians could elect to commence patients at 2000 mg/m 2 . If creatinine clearance was between 30 and 50 ml/min, the starting dose was also 2000 mg/m 2 . As part of the original trial design, pre-defined co-morbidities primarily relating to cardiovascular risk factors were prospectively recorded. Eligibility included: histologically confirmed, metastatic CRC, measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, no prior treatment of advanced disease excepting prior adjuvant chemotherapy >6 months before randomisation and informed consent. Toxicity was evaluated using National Cancer Institute Common Toxicity Criteria version 3.0 (NCIC CTCAE v3). Tumour response was evaluated using RECIST V1.0. Quality of life was assessed using EORTC QLQ C30 and gastric/oesophageal modules.
For this analysis, patients aged 75 years and >75 years at randomisation were analysed separately to those <75 years. Baseline characteristics were compared between randomised treatment groups and age groups using chi-square tests for categorical variables and ANOVA (approximate normal) or Kruskal-Wallis tests (non-normal) for continuous variables. Analyses of PFS and overall survival (OS) were carried out using Cox proportional hazards models, comparing CB versus C and CBM versus C separately within each age group. An interaction term between treatment and age group was added to assess if the treatment effect was different between the two age groups. A further analysis comparing the combined CB and CBM arms against C alone was carried out to give additional power to assess possible differential effects of adding B by age. Similarly, the treatment effect on response rate (RR) was assessed using chi-square tests within each age group, and logistic regression with an age group by treatment term was used to test for an interaction.
results patient characteristics
Of the intention to treat population of 471, 99 patients (21%) were aged ‡75 years. Baseline characteristics were generally well balanced (Table 1) , with the main differences being higher female proportion in CBM arm and a greater frequency of metastases in lung or liver in arms CB and C, respectively. Table 1A summarises patient characteristics based on age group (i.e. <75 versus ‡75 years). For those aged >75 years, the majority of patients (88%) were commenced on a capecitabine dose of 2000 mg/m 2 /day, days 1-14, q21 (78% due to clinician's choice, 22% creatinine clearance 30-50 ml/min) compared with 61% for those aged <75 years (91% clinician's choice, 9% creatinine clearance 30-50 ml/min).
co-morbidities
Pre-defined co-morbidities of interest for an elderly population were: ex/current smoker 13%/2%, diabetes 15%, hypertension 56%, ischaemic heart disease 15% and previous cerebrovascular accident/transient ischaemic attack 10%. Co-morbidity frequencies are similar to reported rates in this population (http://www.aihw.gov.au/cdarf/data_pages/incidence_prevalence/ index.cfm) and the breakdown by arm and by age cohort are summarised in Table 2 and Table 2A , respectively.
outcomes
The significant improvement in PFS as reported in the whole MAX population was also seen in the subpopulation aged over 75 years (C versus CB Hazard ratio (HR) 0.53 [95% confidence interval (CI) 0.32-0.86] P = 0.001, C versus CBM HR 0.38 (95% CI 0.23-0.64) P < 0.001) ( Figure 1 ). OS was not statistically improved by the addition of bevacizumab in keeping with the primary analysis, although there was an apparent trend to better survival in the older group when compared with those <75 years ( Figure 2 ). Interaction test for OS, RR and PFS (PFS) revealed no impact of age as summarised in Table 3 . Subsequent therapy differed based on age group with the proportion of patients receiving all three chemotherapy drugs at some time (5-FU/oxaliplatin/irinotecan) being 10% in those aged over 75 years compared with 20% for those aged <75 years.
toxicity
In those aged ‡75 years, there were no major differences in toxicity between C alone and the pooled bevacizumab arms, apart from a trend to a greater rate of diarrhoea, with the addition of B (Table 4) . Importantly, there were no significant trends to greater bevacizumab-related toxic effects by age. Overall, toxicity rates for the elderly patient group were similar to those aged <75 years (Table 4) .
dose intensity
Dose delivered as a percentage of starting dose and number of cycles is reported in Table 5 . Patients in the capecitabine alone arm received fewer cycles reflecting the earlier progression, but original articles Annals of Oncology there was no difference based on age. Noting the greater proportion of patients commencing capecitabine at 2000 mg/ m 2 /day in the age over 75-year group, there was no apparent difference in dose intensity by age.
discussion
The MAX trial previously reported that PFS is significantly improved by the addition of bevacizumab to capecitabine in advanced CRC. Here, we report that the elderly cohort (aged ‡75 years) has similar improvement in PFS to those <75 years with no apparent increase in toxicity. These findings are important as there remains in general a lack of specific clinical research in the medical management of older cancer patients and a fear that the therapeutic window is more narrow in the elderly [8] . Furthermore, there are few comparative data about the effect of adding biological agents to chemotherapy in the elderly.
In this analysis, we have demonstrated a significant improvement in PFS with the addition of bevacizumab (+/2 MMC) to capecitabine, regardless of age, and this is despite the lower doses of capecitabine used in the elderly. Furthermore, there was also no impact of age on the effects of bevacizumab on PFS, OS, or RR. Previous subgroup analysis of older patients within bevacizumab trials has been presented with similar findings, notably by Kabbinavar et al. [9] , who analysed the pivotal Hurwitz data of bevacizumab combined with irinotecan/5-FU/Leucovrin and the single-agent 5-FU paper [10] and then later updated by Cassidy et al. [6] who also included the first-line oxaliplatin study [11] and the Giantonio second line study [12] . Both analyses compared patients <65 years with >65 years, and <70 years with >70 years. Both reported that the improvement in PFS with bevacizumab was similar regardless of age group. Although this gives some insight into the effects of advancing age, it is important to note that the age cut-offs used in these studies are closer to the median age of patients with metastatic CRC. Our analysis has focussed on an older age group ( ‡75 years) specifically and confirmed the benefit of adding bevacizumab. Of note, these trials also showed an effect of bevacizumab on OS, which was confirmed in the age group sub-analysis. The primary analysis of the MAX trial [7] did not find an OS improvement, possibly as a consequence of the change in practice over recent years, where use of second-and third-line therapy is now far more frequent, obscuring any effect of first-line treatment on OS. This held up in this subgroup analysis, although of note, the use of subsequent therapy was relatively low in both cohorts, possibly reflecting the older age group overall in this study. Despite this, OS was still acceptable and in the elderly cohort reported here, there was a trend to improve overall survival in the bevacizumab-containing arms possibly as a consequence of less use of second-and third-line therapy in the elderly (10% ‡75 years versus 20% <75 years) and therefore, a stronger relationship between first-line chemotherapy and survival. The majority of clinicians elected the lower dose option of capecitabine 2000 mg/m 2 /day (88%) compared with those <75 years (61%), which was allowed as part of the original trial design. This does suggest that clinicians were wary of the potential for greater toxicity based on age. Although there were no major differences in toxicity reported, the potential impact of chosen dose should be taken into account when reviewing these data. Diarrhoea was the only significant toxicity that was higher in the older group overall, but the rate was not increased by the addition of bevacizumab (C 19% versus CB/CBM 21%), in contrast to the younger cohort (C 8% versus CB/CBM 15%).
Bevacizumab is associated with specific toxic effects, in particular hypertension and proteinuria and rarely haemorrhage and intestinal perforation [10] . There was no evidence of an effect of age on the incidence of these effects. For patients receiving bevacizumab, haemorrhage occurred at the same rate in younger and older age cohorts, and there were no gastrointestinal perforations in those aged over 75 years compared with to four cases in patients aged <75 years. We and others have previously confirmed the higher rate of arterial thromboembolic events (ATE) in patients receiving bevacizumab [5, 13] . The current analysis, however, does not suggest an age effect for ATEs (4% aged <75 years, 3.2% aged ‡75 years). This contrasts with previous reports where arterial thromboembolic rates were higher in the elderly patient groups [5, 6] . Cassidy et al. demonstrated ATE rates for chemotherapy versus chemotherapy plus bevacizumab as follows, 2 versus 2% <65 years, 2.5 versus 5.7% ‡65 years and 3.2 versus 6.7% ‡70 years, Figure 1 . Progression-free survival age subgroup comparisons with test for interaction. #Interaction P-value for 'global' interaction test between treatment and age group. *Interaction P-value for the CBevacizumab (CB)/CBMitomycin C (CBM) versus Capecitabine (C) comparison. original articles Annals of Oncology and Scappaticci et al. [5] showed that patients >65 years were twice as likely to have an ATE while on bevacizumab (aged ‡65/ <65 years, HR 2.17 (95% CI 1.17-4.01) P = 0.01). Cassidy [6] concluded that this reflected the normal increase rates based on ageing. Our contrasting results suggest that patient selection factors may be important and potentially screening for significant vascular Grade 5 events: <75 years; none in C, five in CBevacizumab (CB) (sepsis, haemorrhage, perforation), two in CBMitomycin C (CBM) (neutropenic infection, VTE); ‡75 years; one in C (perforation), three in CB (myocarditis, cerebrovascular attack, arterial thromboembolic event), one in CBM (haemorrhage). CNS, central nervous system; PPE, plantar palmar erythema. 
